.jpeg)
{{ variable.name }}
Vansevir (valganciclovir hydrochloride tablets) is an antiviral drug that is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor.
1. Common name : Valganciclovirhydrochloride
2. Trade name :Valcyt e®
3. Dosage form :Film-coated tablets
4. Main ingredients :Each tablet contains valganciclovir hydrochloride 496.3mg (equivalent to valganciclovir 450mg), and excipients include microcrystalline cellulose, povidone K-30, crospovidone and stearic acid. Film coat contains OpadryPink®.
Cytomegalovirus (CMV) retinitis : Used to treat CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
1. Specifications of : 450mg/tablet (calculated as valganciclovir).
2. Characteristics : Film-coated tablets.
1. Induction therapy : 900mg (2 tablets) twice a day, taken with meals for 21 days.
2. Maintenance treatment : 900mg once a day, take with food.
3. Treatment of missed doses : If you miss a dose and it is >4 hours before the next dose, you can take it again, otherwise skip it. No need to take additional doses after vomiting.
5. Dose adjustment
Renal insufficiency : Adjust the dose according to creatinine clearance (CrCl): when CrCl is 40-59mL/min, the induction dose is reduced to 450mg twice a day, and the maintenance dose is 450mg once a day; CrC When CrCl is 25-39 mL/min, the induction dose is 450 mg once a day, and the maintenance dose is 450 mg once every 2 days; when CrCl is 10-24 mL/min, the induction dose is 450 mg once every 2 days, and the maintenance dose is 450 mg twice a week; it is contraindicated in patients with CrCl < 10 mL/min or hemodialysis patients.
1. Influence of diet : Must be taken with food to increase bioavailability.
2. Blood monitoring : Regular blood routine (neutrophils, platelets, hemoglobin) and renal function need to be tested regularly.
3. Neurotoxicity : May cause dizziness or confusion. Avoid driving or operating machinery.
1. Pregnant women: : Disabled (animal experiments show teratogenicity).
2. Lactation : Breastfeeding is prohibited during treatment and for at least 1 week after the last dose.
3. Children : Safety has not been established.
4. Elderly : The dosage needs to be adjusted according to renal function.
1. Common (≥20%) : Diarrhea (41%), nausea (30%), fever (31%), neutropenia (27%), anemia (26%).
2. Severe reactions : Bone marrow suppression (19% neutrophils <500/μL), retinal detachment (15%), acute kidney injury (3%).
1. Those allergic to valganciclovir or cyclovir.
2. Absolute neutrophil count <500/μL or platelet count <25,000/μL.
1. Zidovudine : Increases the risk of anemia and neutropenia.
2. Didanosine : When used in combination, it can increase the AUC of didanosine by 111%.
3. Probenecid : can increase the plasma concentration of ganciclovir by 53%.
1. Store in original packaging, away from light and moisture.
2. Storage temperature: 25°C (short-term fluctuation of 15-30°C is allowed).
Note : CMV viral load and fundus examination need to be monitored regularly during treatment. Avoid taking it with aluminum/magnesium-containing antacids (need to be separated by 2 hours).